EHNA是一種可逆的腺苷脫氨酶抑制劑(人紅細胞中的IC50 = 1.2微米)，它還選擇性地抑制cGMP特異性磷酸二酯酶(PDE2)(人和豬心肌中的IC50分別為0.8和2微米，大鼠肝細胞中為3.5微米，人血小板中為5.5微米)。[1]，[2]相比之下，EHNA抑制PDE1、PDE3或PDE4的能力要弱得多(IC50s > 100微米)。1 EHNA已被用于評估缺血期間的心臟保護和神經(jīng)保護作用，研究cAMP/cGMP信號的作用，以及維持多能性/防止人類(lèi)胚胎干細胞分化。[3],[4][5]

產(chǎn)品性質(zhì)：

Cas No.:58337-38-5

別名:外消旋-9-(2-羥基-3-壬基)腺嘌呤鹽酸鹽

化學(xué)名:(2R,3S)-3-(6-amino-9H-purin-9-yl)nonan-2-ol hydrochloride

Canonical SMILES:O[C@H](C)[C@H](CCCCCC)N1C2=NC=NC(N)=C2N=C1.Cl

分子式:C14H23N5O.HCl

分子量:313.83

溶解度:30mg/mL in DMSO, 30mg/mL in DMF, 20mg/mL in Ethanol, 10mg/mL in Water

儲存條件:Store at -20°C

注意事項：

為了您的安全和健康，請穿實(shí)驗服并戴一次性手套操作。

References:

[1]. Podzuweit, T., Nennstiel, P., and Müller, A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell. Signal. 7(7), 733-738 (1995).[

[2]. Michie, A.M., Lobban, M., Müller, T., et al. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: Analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell. Signal. 8(2), 97-110 (1996).

[3]. Barankiewicz, J., Danks, A.M., Abushanab, E., et al. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors. J. Pharmacol. Exp. Ther. 283(3), 1230-1238 (1997).

[4]. Dickinson, N.T., Jang, E.K., and Haslam, R.J. Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: Effects on platelet aggregation. Biochem. J. 323(Pt. 2), 371-377 (1997).

[5]. Burton, P., Adams, D.R., Abraham, A., et al. Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochem. J. 432(3), 575-584 (2010).